Surface Oncology announced on 4/23/18 the closing of its initial public offering of 7,200,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the... read more
Surface Oncology announced on 4/23/18 the closing of its initial public offering of 7,200,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the... read more
Patients with relapsing remitting multiple sclerosis (RRMS) who received Sanofi Genzyme’s Lemtrada (alemtuzumab) experienced effects of treatment on disease activity that were maintained over... read more
NuProbe Global will commercialize the Harvard Wyss Institute's DNA nanotechnology-based variant-detecting method as a fast, low-cost and multiplexed molecular diagnostic for different disease... read more
GENFIT announced on 4/23/18 that the Data Safety Monitoring Board (DSMB) issued a new positive recommendation for the continuation of the RESOLVE-IT Phase 3 trial evaluating elafibranor in NASH... read more
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced on 4/23/18 that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending... read more